PEPG
PepGen Inc.
Biotechnology
Market Cap$127M
5Y Perf.-83.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PEPG vs FOLD
Revenue, margins, valuation, and 5-year total return — side by side.
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.47B
5Y Perf.+89.8%
PEPG vs FOLD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PEPG | FOLD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $127M | $4.47B |
| Revenue (TTM) | $0.00 | $599M |
| Net Income (TTM) | $-90M | $-14M |
| Gross Margin | — | 89.5% |
| Operating Margin | — | 5.5% |
| Forward P/E | — | 40.6x |
| Total Debt | $17M | $444M |
| Cash & Equiv. | $61M | $214M |
PEPG vs FOLD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PEPG
FOLD
| Stock | May 22 | May 26 | Return |
|---|---|---|---|
| PepGen Inc. (PEPG) | 100 | 16.5 | -83.5% |
| Amicus Therapeutics… (FOLD) | 100 | 189.8 | +89.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PEPG vs FOLD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FOLD leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. PepGen Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
PEPG
PepGen Inc.
The Income Pick
PEPG is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.17
- Lower volatility, beta 0.17, Low D/E 11.5%, current ratio 11.94x
- Beta 0.17, current ratio 11.94x
Best for: income & stability and sleep-well-at-night
FOLD
Amicus Therapeutics, Inc.
The Growth Play
FOLD carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 32.3%, EPS growth 64.7%, 3Y rev CAGR 20.0%
- 125.0% 10Y total return vs PEPG's -85.7%
- 32.3% revenue growth vs PEPG's -1.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FOLD | 32.3% revenue growth vs PEPG's -1.0% |
| Quality / Margins | PEPG | 2.3% margin vs FOLD's -2.3% |
| Stability / Safety | PEPG | Beta 0.17 vs FOLD's 0.63, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | FOLD | +134.1% vs PEPG's +43.0% |
| Efficiency (ROA) | FOLD | -1.6% ROA vs PEPG's -60.4%, ROIC 4.8% vs -73.2% |
PEPG vs FOLD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFOLDLAGGINGPEPG
PEPGPepGen Inc.
0leads
FOLDAmicus Therapeutics, …
3leads
6 Total Categories
CATEGORYLEADERvs PEPGMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FOLD1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FOLD5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
FOLD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FOLD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
FOLD and PEPG operate at a comparable scale, with $599M and $0 in trailing revenue.
| Metric | PEPGPepGen Inc. | FOLDAmicus Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $599M |
| EBITDAEarnings before interest/tax | -$90M | $40M |
| Net IncomeAfter-tax profit | -$90M | -$14M |
| Free Cash FlowCash after capex | -$82M | $10M |
| Gross MarginGross profit ÷ Revenue | — | +89.5% |
| Operating MarginEBIT ÷ Revenue | — | +5.5% |
| Net MarginNet income ÷ Revenue | — | -2.3% |
| FCF MarginFCF ÷ Revenue | — | +1.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +19.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +60.3% | +3.8% |
FOLD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — PEPG and FOLD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | PEPGPepGen Inc. | FOLDAmicus Therapeuti… |
|---|---|---|
| Market CapShares × price | $127M | $4.5B |
| Enterprise ValueMkt cap + debt − cash | $84M | $4.7B |
| Trailing P/EPrice ÷ TTM EPS | -0.87x | -80.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 40.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 140.62x |
| Price / SalesMarket cap ÷ Revenue | — | 8.46x |
| Price / BookPrice ÷ Book value/share | 0.53x | 22.73x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — PEPG and FOLD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
FOLD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
FOLD delivers a -6.1% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-76 for PEPG. PEPG carries lower financial leverage with a 0.12x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 2.29x. On the Piotroski fundamental quality scale (0–9), FOLD scores 5/9 vs PEPG's 4/9, reflecting solid financial health.
| Metric | PEPGPepGen Inc. | FOLDAmicus Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -75.7% | -6.1% |
| ROA (TTM)Return on assets | -60.4% | -1.6% |
| ROICReturn on invested capital | -73.2% | +4.8% |
| ROCEReturn on capital employed | -63.4% | +4.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.12x | 2.29x |
| Net DebtTotal debt minus cash | -$44M | $230M |
| Cash & Equiv.Liquid assets | $61M | $214M |
| Total DebtShort + long-term debt | $17M | $444M |
| Interest CoverageEBIT ÷ Interest expense | — | 1.11x |
FOLD leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
FOLD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FOLD five years ago would be worth $15,094 today (with dividends reinvested), compared to $1,431 for PEPG. Over the past 12 months, FOLD leads with a +134.1% total return vs PEPG's +43.0%. The 3-year compound annual growth rate (CAGR) favors FOLD at 6.0% vs PEPG's -50.2% — a key indicator of consistent wealth creation.
| Metric | PEPGPepGen Inc. | FOLDAmicus Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -74.3% | +1.5% |
| 1-Year ReturnPast 12 months | +43.0% | +134.1% |
| 3-Year ReturnCumulative with dividends | -87.7% | +19.0% |
| 5-Year ReturnCumulative with dividends | -85.7% | +50.9% |
| 10-Year ReturnCumulative with dividends | -85.7% | +125.0% |
| CAGR (3Y)Annualised 3-year return | -50.2% | +6.0% |
FOLD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PEPG and FOLD each lead in 1 of 2 comparable metrics.
Risk & Volatility
PEPG is the less volatile stock with a 0.17 beta — it tends to amplify market swings less than FOLD's 0.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs PEPG's 23.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PEPGPepGen Inc. | FOLDAmicus Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.17x | 0.63x |
| 52-Week HighHighest price in past year | $7.80 | $14.50 |
| 52-Week LowLowest price in past year | $1.01 | $5.51 |
| % of 52W HighCurrent price vs 52-week peak | +23.7% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 39.6 | 72.2 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 3.0M |
Evenly matched — PEPG and FOLD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PEPG as "Buy" and FOLD as "Buy". Consensus price targets imply 279.4% upside for PEPG (target: $7) vs 0.1% for FOLD (target: $15).
| Metric | PEPGPepGen Inc. | FOLDAmicus Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $7.00 | $14.50 |
| # AnalystsCovering analysts | 6 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
FOLD leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallAmicus Therapeutics, Inc. (FOLD)Leads 3 of 6 categories
Loading custom metrics...
PEPG vs FOLD: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is PEPG or FOLD a better buy right now?
Analysts rate PepGen Inc.
(PEPG) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PEPG or FOLD?
Over the past 5 years, Amicus Therapeutics, Inc.
(FOLD) delivered a total return of +50. 9%, compared to -85. 7% for PepGen Inc. (PEPG). Over 10 years, the gap is even starker: FOLD returned +125. 0% versus PEPG's -85. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PEPG or FOLD?
By beta (market sensitivity over 5 years), PepGen Inc.
(PEPG) is the lower-risk stock at 0. 17β versus Amicus Therapeutics, Inc. 's 0. 63β — meaning FOLD is approximately 265% more volatile than PEPG relative to the S&P 500. On balance sheet safety, PepGen Inc. (PEPG) carries a lower debt/equity ratio of 12% versus 2% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — PEPG or FOLD?
On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc.
grew EPS 64. 7% year-over-year, compared to 25. 6% for PepGen Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PEPG or FOLD?
PepGen Inc.
(PEPG) is the more profitable company, earning 0. 0% net margin versus -10. 6% for Amicus Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOLD leads at 4. 7% versus 0. 0% for PEPG. At the gross margin level — before operating expenses — FOLD leads at 90. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is PEPG or FOLD more undervalued right now?
Analyst consensus price targets imply the most upside for PEPG: 279.
4% to $7. 00.
07Which pays a better dividend — PEPG or FOLD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is PEPG or FOLD better for a retirement portfolio?
For long-horizon retirement investors, PepGen Inc.
(PEPG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 17)). Both have compounded well over 10 years (PEPG: -85. 7%, FOLD: +125. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between PEPG and FOLD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PEPG is a small-cap quality compounder stock; FOLD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.